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reservations have restricted market access thus increasing co-pays. This is driven 
by stakeholder concerns on non-compliance leading to drug resistance, promiscuity, 
and development off a false sense of security resulting in a drop in HIV screening 
rates and protective measures. The gravity of the issue is judged by the fact that, 
FDA has called for a REMS to take care of these issues. ConClusions: The utiliza-
tion of a new medical service is impacted by societal perceptions, especially those 
conflicting with general values. In spite of regulatory approvals and national recom-
mendations supported by clinical evidences, low adoption and high co-pays reflects 
that the market access is significantly driven by strong prevailing societal views.
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objeCtives: Two human papillomavirus (HPV) vaccines were licensed to prevent 
HPV infections, but the utilization remains low in the United States (US). Previous 
trend studies about HPV vaccine utilization in the US are scarce and their conclusions 
are subject to internal invalidities due to methodological flaws. This study aimed to 
reinvestigate the trend of HPV vaccine utilization including uptake, completion, and 
adherence by using more accurate measurement and sophisticated statistical meth-
ods. Methods: This was a retrospective cross-sectional study. Subjects aged 11-32 
in the National Health and Nutrition Examination Survey 2011-2012 were extracted. 
Two constructs of the Andersen healthcare utilization model were adapted for vari-
ables selection. Heckman two-step sample selection models along with logistic and 
Poission regressions were performed to examine variables associated with vaccine 
uptake, completion, and adherence. Results: Among study subjects (weighted N= 
92,290,848), 19.7% were HPV vaccine users. Factors positively related to vaccine uptake 
included being female, younger age, going to a doctor’s office or hospital for most 
healthcare services, and having Medicaid or other public insurance. Among HPV vac-
cine users, higher income was positively related to vaccine completion and adher-
ence. Vaccine completion rate did not increase overtime. Nonetheless, subjects who 
received their first dose of HPV vaccine between 2008 to 2010 had better adherence, 
compared with subjects who received their first dose in 2006, the vaccine introduc-
tion year. ConClusions: We observed disparities in HPV vaccine uptake, indicating 
that expanding insurance coverage to HPV vaccine and increasing vaccine access 
through primary care services could be efficient ways to improve the low HPV vaccine 
initiation rate in the US. Additionally, the increasing trend of HPV vaccine utiliza-
tion observed from previous studies could be mistaken due to secular accumulation 
overtime. Because the vaccine completion rate actually did not increase over time, 
more efforts should be addressed to ensure vaccine completion.
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objeCtives: Vaccines are one of the greatest triumphs of healthcare innovation. 
They have saved millions of lives, prevented destructive chronic illnesses and eased 
pressures on health services across the globe. However, it is surprisingly difficult 
for manufacturers trying to navigate the UK government system. We provide an 
outline of the route to potential reimbursement, using recent examples, and guid-
ance based on lessons learned. Methods: Published UK articles, The Health and 
Social Care Act 2012 and government and industry records were scrutinised and 
summarised into an outline of the process to make vaccines available. Examples of 
vaccines, the challenges they have faced and potential solutions to those challenges 
were examined. Results: Once a licence has been obtained, usually through the 
European Medicines Agency, the Joint Committee on Vaccination and Immunisation 
(JCVI), makes recommendations to the Department of Health (DH). The JCVI covers 
all UK countries (subject to potential devolution of powers to Scotland). The JCVI is 
considering allowing industry to attend Committee meetings, which would be a 
huge step forward for such a secretive body. There is no scoping phase, limited stake-
holder engagement; recommendations are not made public and their rationale not 
given, and there is no appeal element to the process. The DH agrees the price of each 
vaccine, which in a recent example took around a year, with input from NHS England 
(NHSE) and Public Health England (PHE). PHE is then responsible for implementation 
and procurement through its Health Protection Directorate. To draw together this 
process, the NHSE and DH jointly convene a Senior Oversight Committee, chaired 
by NHSE. ConClusions: Companies proposing to bring vaccines to market need 
to pay special attention, well in advance, to navigating this complicated structure. 
This is needed to achieve a satisfactory price, which rewards R&D and other costs, 
within a reasonable period.
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objeCtives: Incentivizing antibiotic development in advance of resistance devel-
opment is a critical global health policy issue. A number of policy initiatives are 
under development globally. Some focus on alternative reward mechanisms inclu-
sive of lump sum payments; others focus on enhanced reimbursement once the 
drugs reach market. Understanding how the timing and magnitude of the rewards 
impact antibiotic R&D investment decisions is essential to effective and efficient 
policy development. Methods: The R&D portfolio investment decision process and 
anticipated cash flow for antibiotics is modeled using decision trees composed of 
deterministic decision nodes and probabilistic uncertainties. (e.g., the probability 
of success during phase 2 trials). Monte Carlo simulations and calculations for net 
present values and the decision options at the various nodes are incorporated into 
the decision tree analysis in order to provide insights into the valuations at the vari-
availability of novel 2GDAAs. Treatment patterns are sensitive to market entry of 
new HCV medications. HCV treatment selection and duration may be influenced 
by disease severity and treatment history.
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objeCtives: Cachexia is characterized by a loss in muscle mass leading to an overall 
reduction in function and is often related to severe chronic conditions such as can-
cer, kidney disease and HIV. Anabolic steroids (AS) have been seen as a potential aid 
to reducing the impact of cachexia in HIV patients, but AS therapy remains contro-
versial. The purpose of this study was to characterize HIV related cachexia patients 
and look for differences between those treated or not treated with AS. Methods: 
To complete this study we used Medicare LDS 5% random sample for 2011-2013. 
Patients were identified as having HIV (ICD-9 code 042) and then cachexia (ICD-9 
code 799.4, 783.0, 783.2, and 783.3) using inpatient and outpatient claims. AS treat-
ment was identified using HCPCS J codes. Among those with cachexia, patients 
receiving AS were compared to those who were not using frequencies, means, t-test, 
and chi-square statistics. Results: There were over 4,000 HIV patients in the sam-
ple, 1,835 of which had cachexia. Only 54 patients received AS therapy, but there 
were still differences between treated and non-treated patients in terms of gender 
(90.74% and 72.09%, respectively, p= 0.01) and race (66.67% and 45.65%, respectively, 
p= 0.03). Treated patients had higher CCI scores (11.72 versus 9.75, p= 0.01). In each 
group 75% of individuals received Medicare benefits because of chronic disability. 
Treated and untreated patients had similar ER and inpatient visits as well as simi-
lar total costs ($43,085.76 versus $29,930.82, inpatient, p= 0.07). ConClusions: In 
this study we have seen that in HIV related cachexia those patients who receive AS 
therapy for cachexia are the most severe of an already severely ill group. This study 
indicates that AS treatment is being used as a last resort instead of earlier in the 
cachexic process when the treatment could potentially have a larger impact on a 
patient’s disease progression.
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objeCtives: Over 100,000 people in the UK are living with human immuno-
deficiency virus (HIV). This once acute condition has been transformed into a 
near chronic condition by antiretroviral treatment (ART), providing people living 
with HIV (PLHIV) remain virologically suppressed. In order to maintain suppres-
sion, patients must adhere to ART. Single tablet ART regimens (STRs) are a recent 
advance aimed at improving adherence. However, PLHIV are more likely to develop 
non-AIDS related morbidities (NARMs) including diabetes and chronic kidney 
disease than the general population. Our objective was to develop a HIV model 
with the ability to capture adherence and NARMs, suitable for health technology 
assessments. Methods: A review of HIV models concluded that existing models 
do not adequately account for either adherence benefits associated with STRs or 
the impact of non-AIDS related morbidities. We developed an individual patient 
simulation model in R to predict clinical and economic outcomes of ART in treat-
ment naïve patients. Patients move through a clinically validated treatment path-
way based on previous treatments and standard of care. The probability of viral 
suppression at 48 weeks for each antiretroviral treatment, informed by a recent 
network meta-analysis, determines whether CD4 levels will increase or decrease. 
The level of CD4, along with patient’s characteristics and current antiretroviral 
treatment, are used to predict NARMs, opportunistic infections and morbidities. 
Adherence to treatment modifies the long term probability of remaining virologi-
cally suppressed. Results: Our model predicts overall survival, CD4 over time 
and event rates that concur with long term studies in HIV. The model also predicts 
other clinical and economic outcomes including time on first treatment, QALYs 
and cost, stratified by resource category. ConClusions: This model is the first, 
to our knowledge, to incorporate the adherence benefit of STRs and the impact of 
NARMs on estimates of cost-effectiveness of ART in HIV.
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objeCtives: Studies in literature have shown that the rates of awareness, intent 
and use of HPV vaccines and HIV preventive therapies rose during first years of 
launch but have dropped subsequently. The objective of this study is to assess the 
impact of social and behavioral factors on the acceptance and usage of these thera-
pies. Methods: A detailed review of medical literature, journals, regulatory publi-
cations, and physician blogs on HPV and HIV preventive therapies was conducted. 
Our research has been structured by exemplifying two case studies assessing the 
impact of stakeholders’ opinions on acceptance and adoption of vaccines and pre-
ventive therapies Results: Case study 1 Although EMEA approved HPV vaccines 
in 2006, their coverage remains suboptimal. These vaccines continue to have low 
adoption throughout Europe, compared to other adult vaccines. This is attribut-
able to apprehensive views among stakeholders, such as parents, having concerns 
on promiscuity and vaccine safety. Similar views were observed among European 
press and religious groups. The attitude of physicians also had a nebulous outlook, 
impacting adoption. Case study 2 A similar scenario exists in the US, with PrEP 
HIV preventive therapy. Although medical literature supports the therapy, societal 
